nilotinib: Clinical Trials

17 trials of nilotinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 2 terminated, 2 unknown, 1 recruiting. 17 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 417Completed 11, Terminated 2, Unknown 2, Recruiting 1, Withdrawn 1

Follow nilotinib: new trials by email Literature Review of nilotinib trials Research Report on nilotinib

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Asciminib Roll-over Study
Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phase 4RecruitingNovartis Pharmaceuticals3472022-08-302026-11-09
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia
Imatinib, Nilotinib - Chronyc Myeloid Leukemia
Phase 4UnknownGruppo Italiano Malattie EMatologiche dell'Adulto4502016-11-112022-01-20
Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.
Nilotinib - Chronic Myeloid Leukemia
Phase 4CompletedNovartis Pharmaceuticals1712016-02-182022-07-22
Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib
Nilotinib - Leukemia, Chronic Myeloid
Phase 4UnknownSamsung Medical Center402015-04-012015-03-17
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
AMN107 - Chronic Myeloid Leukemia (CML)
Phase 4WithdrawnNovartis Pharmaceuticals2014-02-012017-04-20
Efficacy and Safety of Nilotinib in CML-CP
Nilotinib - Chronic Myeloid Leukemia, Chronic Phase
Phase 4CompletedSeoul National University Hospital1102013-05-062017-11-06
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Nilotinib - Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST)
Phase 4CompletedNovartis Pharmaceuticals572013-03-292024-02-08
Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy
Nilotinib 300 mg. - Myeloid Leukemia, Chronic
Phase 4TerminatedKing Abdullah International Medical Research Center982013-03-012017-03-07
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
Nilotinib - Chronic Myelogenous Leukemia in Chronic Phase
Phase 4CompletedNovartis Pharmaceuticals1282010-11-012016-02-08
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
nilotinib - CML, Philadelphia Chromosome Positive (Ph+)
Phase 4TerminatedNovartis Pharmaceuticals32010-10-212021-05-20
Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
Nilotinib - CML in Chronic Phase
Phase 4CompletedNovartis Pharmaceuticals10902010-05-012017-02-24
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
Nilotinib - Philadelphia Chromosome Positive, Chronic Myelogenous Leukemia in Chronic Phase
Phase 4CompletedNovartis Pharmaceuticals452009-12-012016-04-08
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
Nilotinib - Chronic Myelogenous Leukemia
Phase 4CompletedNovartis Pharmaceuticals522009-12-012021-07-01
Tasigna in Glivec-resistant or Intolerant Patients in CML
nilotinib - CML, Nilotinib
Phase 4CompletedNovartis Pharmaceuticals932009-02-012017-02-28
Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial
nilotinib - Chronic Myelogenous Leukemia
Phase 4CompletedNovartis Pharmaceuticals192008-12-012016-11-16
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
Nilotinib - Gastrointestinal Stromal Tumors
Phase 4CompletedNovartis Pharmaceuticals342008-08-292026-07-16
Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Nilotinib - Chronic Myeloid Leukemia
Phase 4CompletedNovartis Pharmaceuticals892008-08-012017-02-23

Conditions studied

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (12)  ·  Leukemia (4)  ·  Blast Crisis (2)  ·  Gastrointestinal Stromal Tumors (2)  ·  Leukemia, Myeloid, Chronic-Phase (2)  ·  Myeloproliferative Disorders (1)  ·  Philadelphia Chromosome (1)  ·  Piebaldism (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Sponsors

Novartis Pharmaceuticals (13)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (1)  ·  King Abdullah International Medical Research Center (1)  ·  Samsung Medical Center (1)  ·  Seoul National University Hospital (1)

Countries

Italy (5)  ·  United States (5)  ·  France (4)  ·  Germany (4)  ·  Spain (4)  ·  Austria (3)  ·  Brazil (3)  ·  Canada (3)  ·  Netherlands (3)  ·  Poland (3)  ·  South Korea (3)  ·  United Kingdom (3)  ·  Bulgaria (2)  ·  Czechia (2)  ·  Denmark (2)

Top investigators

Dr. Ahmad S. Alaskar, MD,FACP,FRCP (1)  ·  Fabrizio Pane (1)  ·  Inho Kim, MD (1)

Results publications

PMID 26993758, PMID 27006491, PMID 27771544, PMID 28522574, PMID 29577674, PMID 30912699

NIH funding

2008 (1), 2009 (1), 2015 (1), 2023 (1)